Literature DB >> 7543184

Inhibition of nicotinic acetylcholine receptor channels in bovine adrenal chromaffin cells by Y3-type neuropeptide Y receptors via the adenylate cyclase/protein kinase A system.

W Nörenberg1, M Bek, N Limberger, K Takeda, P Illes.   

Abstract

The effect of neuropeptide Y [NPY(1-36)] and related peptides on the voltage-dependent currents and the nicotinic acetylcholine receptor (nAChR) currents (IACh) of bovine adrenal chromaffin cells was investigated using the whole-cell patch clamp technique. Catecholamine release from single chromaffin cells was measured by means of fast cyclic voltammetry. The potency order of these peptides in inhibiting IACh evoked by nicotine was NPY(1-36), NPY (16-36) > peptide YY(PYY) > [Leu31, Pro34]NPY. NPY(16-36) produced a similar degree of inhibition, irrespective of whether nicotine or an equipotent concentration of acetylcholine was used to evoke IACh. NPY(16-36) failed to alter voltage-dependent inward or outward currents. Intracellular cAMP, and extracellular dibutyryl-cAMP, produced a slowly developing increase in IACh. Intracellular cAMP, extracellular 8-Br-cAMP or dibutyryl-cAMP, and an inhibitor of cyclic nucleotide phosphodiesterases 3-isobutyl-1-methyl-xanthine (IBMX), decreased the inhibitory effect of NPY(16-36) on IACh. Although the intracellular application of the cAMP-dependent protein kinase A inhibitor [PKI(14-24)amide] alone did not alter IACh, it potentiated the effect of NPY(16-36) in interaction experiments. While the NPY(16-36)-induced inhibition of IACh was reversed on washout of the peptide, the slightly shorter C-terminal fragment NPY(18-36) caused a long-lasting depression of both IACh and catecholamine secretion evoked by nicotine. This depression was smaller in the presence of extracellular 8-Br-cAMP than in its absence. NPY(18-36) did not alter the secretory activity induced by a high concentration of potassium. It appears that, by activating Y3-receptors, NPY inhibits nAChR-current and the resulting secretion of catecholamines from bovine chromaffin cells. This process may involve a G protein-mediated decrease in intracellular cAMP with a subsequent decrease in the degree of phosphorylation of the nAChR-channel.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7543184     DOI: 10.1007/bf00169073

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  47 in total

Review 1.  Receptors for neuropeptide Y: multiple subtypes and multiple second messengers.

Authors:  M C Michel
Journal:  Trends Pharmacol Sci       Date:  1991-10       Impact factor: 14.819

2.  Cyclic AMP regulates the proportion of functional acetylcholine receptors on chicken ciliary ganglion neurons.

Authors:  J F Margiotta; D K Berg; V E Dionne
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

Review 3.  The role of neuropeptide Y in cardiovascular regulation.

Authors:  P Walker; E Grouzmann; M Burnier; B Waeber
Journal:  Trends Pharmacol Sci       Date:  1991-03       Impact factor: 14.819

4.  Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches.

Authors:  O P Hamill; A Marty; E Neher; B Sakmann; F J Sigworth
Journal:  Pflugers Arch       Date:  1981-08       Impact factor: 3.657

5.  Neuropeptide Y--a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide.

Authors:  K Tatemoto; M Carlquist; V Mutt
Journal:  Nature       Date:  1982-04-15       Impact factor: 49.962

6.  Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function.

Authors:  J M Lundberg; L Terenius; T Hökfelt; C R Martling; K Tatemoto; V Mutt; J Polak; S Bloom; M Goldstein
Journal:  Acta Physiol Scand       Date:  1982-12

7.  Release of NPY-like immunoreactive material from primary cultures of chromaffin cells prepared from bovine adrenal medulla.

Authors:  Y Kataoka; E A Majane; H Y Yang
Journal:  Neuropharmacology       Date:  1985-07       Impact factor: 5.250

8.  Enhancement of stimulation-evoked catecholamine release from cultured bovine adrenal chromaffin cells by forskolin.

Authors:  K Morita; T Dohi; S Kitayama; Y Koyama; A Tsujimoto
Journal:  J Neurochem       Date:  1987-01       Impact factor: 5.372

9.  Neuropeptide Y inhibits forskolin-stimulated adenylate cyclase in bovine adrenal chromaffin cells via a pertussis toxin-sensitive process.

Authors:  J Zhu; W Li; M L Toews; T D Hexum
Journal:  J Pharmacol Exp Ther       Date:  1992-12       Impact factor: 4.030

10.  Cyclic AMP-dependent mechanism regulates acetylcholine receptor function on bovine adrenal chromaffin cells and discriminates between new and old receptors.

Authors:  L S Higgins; D K Berg
Journal:  J Cell Biol       Date:  1988-09       Impact factor: 10.539

View more
  4 in total

1.  Deletion of the neuropeptide Y (NPY) Y1 receptor gene reveals a regulatory role of NPY on catecholamine synthesis and secretion.

Authors:  Cláudia Cavadas; Daniel Céfai; Joana Rosmaninho-Salgado; Maria Augusta Vieira-Coelho; Eduardo Moura; Nathalie Busso; Thierry Pedrazzini; Daniela Grand; Samuel Rotman; Bernard Waeber; Jean-François Aubert; Eric Grouzmann
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-23       Impact factor: 11.205

Review 2.  Interaction of P2 purinergic receptors with cellular macromolecules.

Authors:  Laszlo Köles; Zoltan Gerevich; João Felipe Oliveira; Zoltan Sandor Zadori; Kerstin Wirkner; Peter Illes
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-19       Impact factor: 3.000

3.  Neuropeptide Y modulates ATP-induced increases in internal calcium via the adenylate cyclase/protein kinase A system in a human neuroblastoma cell line.

Authors:  V Soares Lemos; B Bucher; K Takeda
Journal:  Biochem J       Date:  1997-01-15       Impact factor: 3.857

4.  Regulation of neuronal ion channels via P2Y receptors.

Authors:  Stefan G Lechner; Stefan Boehm
Journal:  Purinergic Signal       Date:  2004-12       Impact factor: 3.765

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.